array:24 [
  "pii" => "S0001731024002825"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2024.04.001"
  "estado" => "S300"
  "fechaPublicacion" => "2024-06-01"
  "aid" => "3930"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2024;115:T615-T617"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731024000565"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.12.005"
    "estado" => "S300"
    "fechaPublicacion" => "2024-06-01"
    "aid" => "3820"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:618-24"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENT&#205;FICO-CL&#205;NICA</span>"
      "titulo" => "Tralokinumab en dermatitis at&#243;pica&#58; datos de pr&#225;ctica cl&#237;nica en un hospital de tercer nivel en Espa&#241;a"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "618"
          "paginaFinal" => "624"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Tralokinumab in Atopic Dermatitis&#58; Real-Life Data from a Spanish Tertiary Referral Center"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Gr&#225;fica 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 846
              "Ancho" => 1500
              "Tamanyo" => 62235
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evaluaci&#243;n de la efectividad mediante la escala SCORAD seg&#250;n semana 16 y 24 de tratamiento&#46; Se visualiza el porcentaje de pacientes que alcanz&#243; las respuestas objetivo&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46;M&#46; Dom&#237;nguez-Santana, M&#46; Viedma-Mart&#237;nez, E&#46; R&#237;os-S&#225;nchez"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "C&#46;M&#46;"
              "apellidos" => "Dom&#237;nguez-Santana"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Viedma-Mart&#237;nez"
            ]
            2 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "R&#237;os-S&#225;nchez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000565?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000565/v1_202406021150/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731024000516"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.07.026"
    "estado" => "S300"
    "fechaPublicacion" => "2024-06-01"
    "aid" => "3811"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:615-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "615"
          "paginaFinal" => "617"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2144
              "Ancho" => 2508
              "Tamanyo" => 236604
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; and SCORAD&#44; DLQI&#44; and BSA &#40;median&#41; over time&#46; EASI&#44; Eczema Area and Severity Index&#59; IGA-AD&#44; Validated Investigator Global Assessment for Atopic Dermatitis of 0 or 1&#59; SCORAD&#44; SCORing Atopic Dermatitis&#59; DLQI&#44; Dermatology Life Quality Index&#59; BSA&#44; body surface area&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span>-test was used&#44; when necessary&#44; to calculate statistical differences&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>&#46;001 for differences vs baseline&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Naharro-Rodr&#237;guez"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Bern&#225;-Rico"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "P&#233;rez-Bootello"
            ]
            3 => array:2 [
              "nombre" => "B&#46;"
              "apellidos" => "P&#233;rez-Garc&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000516?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000516/v1_202406021150/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731024000516"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.07.026"
      "estado" => "S300"
      "fechaPublicacion" => "2024-06-01"
      "aid" => "3811"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2024;115:615-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
        "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "615"
            "paginaFinal" => "617"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 2144
                "Ancho" => 2508
                "Tamanyo" => 236604
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; and SCORAD&#44; DLQI&#44; and BSA &#40;median&#41; over time&#46; EASI&#44; Eczema Area and Severity Index&#59; IGA-AD&#44; Validated Investigator Global Assessment for Atopic Dermatitis of 0 or 1&#59; SCORAD&#44; SCORing Atopic Dermatitis&#59; DLQI&#44; Dermatology Life Quality Index&#59; BSA&#44; body surface area&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span>-test was used&#44; when necessary&#44; to calculate statistical differences&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>&#46;001 for differences vs baseline&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Naharro-Rodr&#237;guez"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Bern&#225;-Rico"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "P&#233;rez-Bootello"
              ]
              3 => array:2 [
                "nombre" => "B&#46;"
                "apellidos" => "P&#233;rez-Garc&#237;a"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000516?idApp=UINPBA000044"
      "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000516/v1_202406021150/en/main.assets"
    ]
  ]
  "es" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Cartas cient&#237;fico-cl&#237;nicas</span>"
    "titulo" => " Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sr&#46; Director&#44;</span>"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T615"
        "paginaFinal" => "T617"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "J&#46;"
            "apellidos" => "Naharro-Rodr&#237;guez"
            "email" => array:1 [
              0 => "jorgenrmed@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "E&#46;"
            "apellidos" => "Bern&#225;-Rico"
          ]
          2 => array:2 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "P&#233;rez-Bootello"
          ]
          3 => array:2 [
            "nombre" => "B&#46;"
            "apellidos" => "P&#233;rez-Garc&#237;a"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Dermatology Department&#44; Ram&#243;n y Cajal University Hospital&#44; IRYCIS&#44; Madrid&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2144
            "Ancho" => 2508
            "Tamanyo" => 244013
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; y SCORAD&#44; DLQI y BSA &#40;mediana&#41; a lo largo del tiempo&#46; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Investigator Global Assessment for Atopic Dermatitis validado de 0 o 1&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; DLQI&#58; Dermatology Life Quality Index&#59; BSA&#58; &#225;rea de superficie corporal&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se utiliz&#243; la prueba <span class="elsevierStyleItalic">U</span> de Mann&#8211;Whitney&#44; cuando fue necesario&#44; para calcular las diferencias estad&#237;sticas&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>0&#44;001 para las diferencias con respecto a los valores basales&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Upadacitinib es un inhibidor oral de la quinasa Janus &#40;JAKi&#41;&#44; aprobado para tratar la dermatitis at&#243;pica &#40;DA&#41; de moderada a grave de los pacientes &#8805;<span class="elsevierStyleHsp" style=""></span>12 a&#241;os&#46; Su perfil de eficacia y seguridad en comparaci&#243;n con el placebo ya ha sido demostrado en ensayos cl&#237;nicos<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a>&#44; y se est&#225;n comenzando a reportar datos de la vida real en la literatura m&#233;dica cient&#237;fica&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Realizamos un estudio de cohorte retrospectivo recopilando datos de adolescentes y adultos con dermatitis at&#243;pica refractaria grave tratados diariamente con 30<span class="elsevierStyleHsp" style=""></span>mg de upadacitinib desde mayo de 2022 a abril de 2023 en la Unidad de Dermatolog&#237;a del Hospital Universitario Ramon y Cajal&#44; Madrid&#44; Espa&#241;a&#46; Su efectividad fue medida utilizando la escala IGA-AD &#40;Investigator Global Assessment for Atopic Dermatitis&#41; validada &#40;puntuaciones de 0 o 1 con reducci&#243;n &#8805;<span class="elsevierStyleHsp" style=""></span>2 grados con respecto al valor basal&#41;&#44; y el logro por parte de los pacientes de un valor 75 en la escala EASI &#40;Eczema Area and Severity Index&#41; en las semanas 4&#44; 12 y 24&#46; Se recopilaron todos los acontecimientos adversos &#40;AA&#41; relacionados con el tratamiento&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Se incluyeron once pacientes&#44; con edades que oscilaron de 13 a 52 a&#241;os &#40;mediana&#44; 29&#41;&#46; Todos ellos hab&#237;an sido tratados insatisfactoriamente con corticosteroides t&#243;picos y orales y ciclosporina&#44; 10&#47;11 &#40;90&#44;9&#37;&#41; segu&#237;an tratamiento de dupilumab&#44; y 1&#47;11 &#40;9&#44;1&#37;&#41; segu&#237;an tratamiento de baricitinib&#44; sin lograr un control de la enfermedad aceptable&#46; Las caracter&#237;sticas basales se reflejan en la <a class="elsevierStyleCrossRef" href="#tbl0005">Tabla 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">En cuanto a la efectividad&#44; todos los pacientes reportaron alivio r&#225;pido del prurito&#44; que fue absoluto en el 72&#44;7&#37; de los pacientes&#59; en dichos pacientes&#44; el tiempo de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>rango intercuart&#237;lico &#40;RIC&#41; para el control fue de 4 d&#237;as &#40;2&#44;5&#8211;5&#41;&#46; Al inicio&#44; los valores de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RIC para EASI e IGA-AD fueron de 28 &#40;25&#44;50&#8211;34&#44;25&#41; y 4 &#40;3&#8211;4&#41;&#44; respectivamente&#44; el valor del &#237;ndice SCORAD fue de 58 &#40;51&#8211;60&#41;&#44; y el del &#225;rea de superficie corporal &#40;BSA&#41; afectada de 35 &#40;20&#8211;62&#44;25&#41;&#46; En cuanto a las medidas del resultado reportadas por el paciente&#44; los valores de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RIC para la escala num&#233;rica &#40;NRS&#41; del prurito m&#225;ximo y de DLQI fueron de 6&#44;50 &#40;5&#44;25&#8211;8&#41; y 18 &#40;13&#8211;21&#41;&#44; respectivamente&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">EASI75 &#40;&#8805;75&#37; reducci&#243;n desde el valor de EASI basal&#41; fue logrado por el 90&#44;9&#44; el 81&#44;8 y el 81&#44;8&#37; de los pacientes en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; Las puntuaciones IGA-AD de 0&#8211;1 fueron logradas por el 81&#44;8&#44; 72&#44;7 y 72&#44;7&#37; de los pacientes en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; Los valores medios de DLQI durante el seguimiento fueron de 4&#44; 2&#44; y 2 en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; La eficacia del tratamiento durante el seguimiento se muestra en la <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">En cuanto a las AA&#44; los pacientes presentaron al menos una AA leve&#46; Anal&#237;ticamente&#44; todos los pacientes presentaron incrementos ligeros de los niveles de creatina quinasa en alg&#250;n momento del seguimiento&#46; Otros hallazgos fueron hipercolesterolemia &#40;54&#44;5&#37;&#41;&#44; hipertrigliceridemia &#40;18&#44;2&#37;&#41; e incremento leve de las transaminasas hep&#225;ticas &#40;9&#44;1&#37;&#41;&#46; En cuanto a trastornos infecciosos&#44; 1&#47;12 &#40;9&#44;1&#37;&#41; experimentaron un episodio de herpes z&#243;ster multimetam&#233;rico&#46; No se registraron AA cl&#237;nicos o anal&#237;ticos graves&#46; Todos los AA reportados se muestran en la <a class="elsevierStyleCrossRef" href="#tbl0010">Tabla 2</a>&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Los ensayos cl&#237;nicos MEASURE UP 1 y 2 lograron un valor EASI75 en el 76&#44;3&#37; de los pacientes en la 16&#170; semana de seguimiento&#44; mientras que nosotros observamos un valor EASI75 ligeramente mejor en las semanas 12 y 24 &#40;81&#44;8&#37; en ambas&#41;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a>&#46; En estudios previos sobre la pr&#225;ctica cl&#237;nica real con muestras de mayor tama&#241;o&#44; Pereyra-Rodriguez et al&#46; reportaron un valor de respuestas EASI75 e IGA-AD en la 16&#170; semana del 76&#44;7 y 62&#44;8&#37;&#44; respectivamente &#40;muestra de 43 pacientes&#41;&#44; lo cual es inferior a nuestros hallazgos<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a>&#46; Por otro lado&#44; Chiricozzi et al&#46; reportaron resultados m&#225;s altos en t&#233;rminos de EASI75 en la 16&#170; semana &#40;97&#44;5&#37;&#41; en una muestra de 43 pacientes<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">3</span></a>&#46; Centr&#225;ndonos en los estudios que incluyen &#250;nicamente pacientes con DA refractaria&#44; como el nuestro &#40;inefectividad de dupilumab o JAKi&#41;&#44; Feraru et al&#46; encontraron una respuesta IGA-AD similar a la de nuestro estudio en la semana 24&#170; de seguimiento en 12 adultos &#40;75&#37;&#41;&#44; mientras que De Greef et al&#46; reportaron una respuesta IGA-AD ligeramente menor &#40;71&#44;4&#37;&#41; durante el seguimiento a largo plazo<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">4&#44;5</span></a>&#46; En los estudios con seguimientos m&#225;s breves&#44; Dal Bello et al&#46; lograron un resultado EASI75 en los 10 pacientes con DA refractaria incluidos en el estudio en la 8<span class="elsevierStyleHsp" style=""></span>&#170; semana de seguimiento&#44; mientras que Napolitano et al&#46; reportaron un valor EASI75 del 75&#37; &#40;16 pacientes incluidos&#41; en la 16&#170; semana de seguimiento<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">6&#44;7</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Debemos mencionar el excelente control del prurito logrado por upadacitinib en nuestra serie &#40;72&#44;7&#37; de los pacientes frente al 60&#37; reportado en los ensayos cl&#237;nicos&#41;&#44; y el breve periodo de tiempo transcurrido hasta la remisi&#243;n del prurito de los pacientes &#40;mediana&#44; 4 d&#237;as&#41;&#44; variable no considerada en estudios previos y que debe ser de inter&#233;s&#44; dado que el prurito representa el s&#237;ntoma principal relacionado con la DA&#44; y tiene un impacto directo en la calidad de vida del paciente&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">En conclusi&#243;n&#44; nuestros hallazgos sobre eficacia son consistentes con los reportados tanto en ensayos cl&#237;nicos como en informes de la pr&#225;ctica cl&#237;nica previos&#46; Seg&#250;n nuestra experiencia&#44; upadacitinib es una opci&#243;n fiable cuando las circunstancias del paciente demandan un r&#225;pido alivio del prurito&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">La fortaleza de nuestro estudio es que se trat&#243; de una experiencia en la pr&#225;ctica cl&#237;nica real de los pacientes con DA refractaria a m&#250;ltiples tratamientos&#46; Las limitaciones principales del estudio incluyen el peque&#241;o tama&#241;o de la muestra y la recopilaci&#243;n retrospectiva de los datos&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicto de intereses</span><p id="par0055" class="elsevierStylePara elsevierViewall">Los autores declaran la ausencia de conflicto de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicto de intereses"
        ]
        1 => array:1 [
          "titulo" => "Referencias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2144
            "Ancho" => 2508
            "Tamanyo" => 244013
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; y SCORAD&#44; DLQI y BSA &#40;mediana&#41; a lo largo del tiempo&#46; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Investigator Global Assessment for Atopic Dermatitis validado de 0 o 1&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; DLQI&#58; Dermatology Life Quality Index&#59; BSA&#58; &#225;rea de superficie corporal&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se utiliz&#243; la prueba <span class="elsevierStyleItalic">U</span> de Mann&#8211;Whitney&#44; cuando fue necesario&#44; para calcular las diferencias estad&#237;sticas&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>0&#44;001 para las diferencias con respecto a los valores basales&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">AD&#58; dermatitis at&#243;pica&#59; NB-UVB&#58; rayos ultravioleta B de banda estrecha&#59; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Validated Investigator Global Assessment for Atopic Dermatitis&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; NRS&#58; escala num&#233;rica&#59; BSA&#58; &#225;rea de superficie corporal&#59; DLQI&#58; Dermatology Life Quality Index&#59; RIC&#58; rango intercuart&#237;lico&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#225;metro&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes&#44; n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Edad&#44; a&#241;os&#59; rango &#40;mediana&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#8211;52 &#40;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo masculino&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;45&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Duraci&#243;n de la DA&#44; a&#241;os&#59; mediana &#40;RIC&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;18&#8211;34&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedad renal&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedad hep&#225;tica&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Comorbilidades at&#243;picas&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Rinitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;45&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Asma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Conjuntivitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alergia alimentaria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;81&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatitis por contacto&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">F&#225;rmacos t&#243;picos previos para DA&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inhibidores de calcineurina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tratamientos sist&#233;micos previos para DA&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Baricitinib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Ciclosporina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fototerapia NB-UVB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dupilumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;90&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Basal</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EASI&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28 &#40;25&#44;50&#8211;34&#44;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IGA-AD&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#44;00&#8211;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>SCORAD&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">58 &#40;51&#8211;60&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BSA&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35 &#40;20&#8211;62&#44;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>NRS de prurito&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;50 &#40;5&#44;25&#8211;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">DLQI&#59; mediana &#40;RIC&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;13&#8211;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3555923.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nicas y demogr&#225;ficas basales de los pacientes con dermatitis at&#243;pica grave que reciben upadacitinib</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">EA&#58; efectos adversos&#59; CK&#58; creatina quinasa&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Acn&#233;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cefalea</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Conjuntivitis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastorno GI</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Malestar</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hallazgos de laboratorio</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipercolesterolemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipertrigliceridemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Niveles elevados de transaminasas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Nivel elevado de CK&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Infecciosos</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Herpes z&#243;ster&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Infecciones del tracto respiratorio superior&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Reactivaci&#243;n de herpes simplex&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Graves</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Episodios cardiovasculares&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Episodios tromboemb&#243;licos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cualquier EA</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3555924.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Datos sobre seguridad de los pacientes con dermatitis at&#243;pica grave que reciben upadacitinib</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Referencias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:7 [
            0 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis &#40;Measure Up 1 and Measure Up 2&#41;&#58; results from two replicate double-blind&#44; randomised controlled phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Guttman-Yassky"
                            1 => "H&#46;D&#46; Teixeira"
                            2 => "E&#46;L&#46; Simpson"
                            3 => "K&#46;A&#46; Papp"
                            4 => "A&#46;L&#46; Pangan"
                            5 => "A&#46; Blauvelt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00588-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2151"
                        "paginaFinal" => "2168"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34023008"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of severe atopic dermatitis with upadacitinib in clinical practice&#58; short-term efficacy and safety results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;J&#46; Pereyra-Rodriguez"
                            1 => "P&#46; Herranz"
                            2 => "I&#46; Figueras-Nart"
                            3 => "B&#46; Perez"
                            4 => "M&#46; Elosua"
                            5 => "C&#46; Munera-Campos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.18176/jiaci.0831"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Investig Allergol Clin Immunol"
                        "fecha" => "2023"
                        "volumen" => "33"
                        "paginaInicial" => "211"
                        "paginaFinal" => "213"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35671128"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis&#58; a multicentric&#44; prospective&#44; real-world&#44; cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Chiricozzi"
                            1 => "N&#46; Gori"
                            2 => "A&#46; Narcisi"
                            3 => "A&#46; Balato"
                            4 => "A&#46; Gambardella"
                            5 => "M&#46; Ortoncelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Drugs R D"
                        "fecha" => "2022"
                        "volumen" => "22"
                        "paginaInicial" => "245"
                        "paginaFinal" => "252"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis &#8211; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Feraru"
                            1 => "M&#46;J&#46; Nevet"
                            2 => "L&#46; Samuelov"
                            3 => "E&#46; Hodak"
                            4 => "E&#46; Avitan-Hersh"
                            5 => "M&#46; Ziv"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18311"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e832"
                        "paginaFinal" => "e833"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35680538"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; De Greef"
                            1 => "P&#46;D&#46; Ghislain"
                            2 => "L&#46; de Montjoye"
                            3 => "M&#46; Baeck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12325-023-02490-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Ther"
                        "fecha" => "2023"
                        "volumen" => "40"
                        "paginaInicial" => "2509"
                        "paginaFinal" => "2514"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36944819"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib in patients with resistant atopic dermatitis&#58; a retrospective case-series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46; Dal Bello"
                            1 => "D&#46; Schena"
                            2 => "G&#46; Girolomoni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18139"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "1499"
                        "paginaFinal" => "1500"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35398938"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis&#58; a 16-week real-life dual-centre experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Napolitano"
                            1 => "L&#46; Potestio"
                            2 => "K&#46; Hansel"
                            3 => "R&#46; Marietti"
                            4 => "I&#46; Piscitelli"
                            5 => "G&#46; Fabbrocini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ced/llac078"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol"
                        "fecha" => "2023"
                        "volumen" => "48"
                        "paginaInicial" => "247"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36763761"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024002825/v1_202406021150/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6160"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas cient&#237;fico-cl&#237;nicas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000006/v1_202406021150/S0001731024002825/v1_202406021150/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024002825?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Cartas científico-clínicas
Experiencia en práctica clínica real con upadacitinib en adolescentes y adultos con dermatitis atópica refractaria: un estudio retrospectivo de 24 semanas
Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis: A 24-week Retrospective Study
J. Naharro-Rodríguez
Autor para correspondencia
jorgenrmed@gmail.com

Autor para correspondencia.
, E. Berná-Rico, F.J. Pérez-Bootello, B. Pérez-García
Dermatology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, España
Leído
1911
Veces
se ha leído el artículo
455
Total PDF
1456
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S0001731024002825"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2024.04.001"
  "estado" => "S300"
  "fechaPublicacion" => "2024-06-01"
  "aid" => "3930"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2024;115:T615-T617"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731024000565"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.12.005"
    "estado" => "S300"
    "fechaPublicacion" => "2024-06-01"
    "aid" => "3820"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:618-24"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENT&#205;FICO-CL&#205;NICA</span>"
      "titulo" => "Tralokinumab en dermatitis at&#243;pica&#58; datos de pr&#225;ctica cl&#237;nica en un hospital de tercer nivel en Espa&#241;a"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "618"
          "paginaFinal" => "624"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Tralokinumab in Atopic Dermatitis&#58; Real-Life Data from a Spanish Tertiary Referral Center"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Gr&#225;fica 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 846
              "Ancho" => 1500
              "Tamanyo" => 62235
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evaluaci&#243;n de la efectividad mediante la escala SCORAD seg&#250;n semana 16 y 24 de tratamiento&#46; Se visualiza el porcentaje de pacientes que alcanz&#243; las respuestas objetivo&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46;M&#46; Dom&#237;nguez-Santana, M&#46; Viedma-Mart&#237;nez, E&#46; R&#237;os-S&#225;nchez"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "C&#46;M&#46;"
              "apellidos" => "Dom&#237;nguez-Santana"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Viedma-Mart&#237;nez"
            ]
            2 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "R&#237;os-S&#225;nchez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000565?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000565/v1_202406021150/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731024000516"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.07.026"
    "estado" => "S300"
    "fechaPublicacion" => "2024-06-01"
    "aid" => "3811"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:615-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "615"
          "paginaFinal" => "617"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2144
              "Ancho" => 2508
              "Tamanyo" => 236604
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; and SCORAD&#44; DLQI&#44; and BSA &#40;median&#41; over time&#46; EASI&#44; Eczema Area and Severity Index&#59; IGA-AD&#44; Validated Investigator Global Assessment for Atopic Dermatitis of 0 or 1&#59; SCORAD&#44; SCORing Atopic Dermatitis&#59; DLQI&#44; Dermatology Life Quality Index&#59; BSA&#44; body surface area&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span>-test was used&#44; when necessary&#44; to calculate statistical differences&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>&#46;001 for differences vs baseline&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Naharro-Rodr&#237;guez"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Bern&#225;-Rico"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "P&#233;rez-Bootello"
            ]
            3 => array:2 [
              "nombre" => "B&#46;"
              "apellidos" => "P&#233;rez-Garc&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000516?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000516/v1_202406021150/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731024000516"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.07.026"
      "estado" => "S300"
      "fechaPublicacion" => "2024-06-01"
      "aid" => "3811"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2024;115:615-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
        "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "615"
            "paginaFinal" => "617"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 2144
                "Ancho" => 2508
                "Tamanyo" => 236604
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; and SCORAD&#44; DLQI&#44; and BSA &#40;median&#41; over time&#46; EASI&#44; Eczema Area and Severity Index&#59; IGA-AD&#44; Validated Investigator Global Assessment for Atopic Dermatitis of 0 or 1&#59; SCORAD&#44; SCORing Atopic Dermatitis&#59; DLQI&#44; Dermatology Life Quality Index&#59; BSA&#44; body surface area&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span>-test was used&#44; when necessary&#44; to calculate statistical differences&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>&#46;001 for differences vs baseline&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Naharro-Rodr&#237;guez"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Bern&#225;-Rico"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "P&#233;rez-Bootello"
              ]
              3 => array:2 [
                "nombre" => "B&#46;"
                "apellidos" => "P&#233;rez-Garc&#237;a"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000516?idApp=UINPBA000044"
      "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024000516/v1_202406021150/en/main.assets"
    ]
  ]
  "es" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Cartas cient&#237;fico-cl&#237;nicas</span>"
    "titulo" => " Experiencia en pr&#225;ctica cl&#237;nica real con upadacitinib en adolescentes y adultos con dermatitis at&#243;pica refractaria&#58; un estudio retrospectivo de 24 semanas"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sr&#46; Director&#44;</span>"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T615"
        "paginaFinal" => "T617"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "J&#46; Naharro-Rodr&#237;guez, E&#46; Bern&#225;-Rico, F&#46;J&#46; P&#233;rez-Bootello, B&#46; P&#233;rez-Garc&#237;a"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "J&#46;"
            "apellidos" => "Naharro-Rodr&#237;guez"
            "email" => array:1 [
              0 => "jorgenrmed@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "E&#46;"
            "apellidos" => "Bern&#225;-Rico"
          ]
          2 => array:2 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "P&#233;rez-Bootello"
          ]
          3 => array:2 [
            "nombre" => "B&#46;"
            "apellidos" => "P&#233;rez-Garc&#237;a"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Dermatology Department&#44; Ram&#243;n y Cajal University Hospital&#44; IRYCIS&#44; Madrid&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis&#58; A 24-week Retrospective Study"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2144
            "Ancho" => 2508
            "Tamanyo" => 244013
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; y SCORAD&#44; DLQI y BSA &#40;mediana&#41; a lo largo del tiempo&#46; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Investigator Global Assessment for Atopic Dermatitis validado de 0 o 1&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; DLQI&#58; Dermatology Life Quality Index&#59; BSA&#58; &#225;rea de superficie corporal&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se utiliz&#243; la prueba <span class="elsevierStyleItalic">U</span> de Mann&#8211;Whitney&#44; cuando fue necesario&#44; para calcular las diferencias estad&#237;sticas&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>0&#44;001 para las diferencias con respecto a los valores basales&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Upadacitinib es un inhibidor oral de la quinasa Janus &#40;JAKi&#41;&#44; aprobado para tratar la dermatitis at&#243;pica &#40;DA&#41; de moderada a grave de los pacientes &#8805;<span class="elsevierStyleHsp" style=""></span>12 a&#241;os&#46; Su perfil de eficacia y seguridad en comparaci&#243;n con el placebo ya ha sido demostrado en ensayos cl&#237;nicos<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a>&#44; y se est&#225;n comenzando a reportar datos de la vida real en la literatura m&#233;dica cient&#237;fica&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Realizamos un estudio de cohorte retrospectivo recopilando datos de adolescentes y adultos con dermatitis at&#243;pica refractaria grave tratados diariamente con 30<span class="elsevierStyleHsp" style=""></span>mg de upadacitinib desde mayo de 2022 a abril de 2023 en la Unidad de Dermatolog&#237;a del Hospital Universitario Ramon y Cajal&#44; Madrid&#44; Espa&#241;a&#46; Su efectividad fue medida utilizando la escala IGA-AD &#40;Investigator Global Assessment for Atopic Dermatitis&#41; validada &#40;puntuaciones de 0 o 1 con reducci&#243;n &#8805;<span class="elsevierStyleHsp" style=""></span>2 grados con respecto al valor basal&#41;&#44; y el logro por parte de los pacientes de un valor 75 en la escala EASI &#40;Eczema Area and Severity Index&#41; en las semanas 4&#44; 12 y 24&#46; Se recopilaron todos los acontecimientos adversos &#40;AA&#41; relacionados con el tratamiento&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Se incluyeron once pacientes&#44; con edades que oscilaron de 13 a 52 a&#241;os &#40;mediana&#44; 29&#41;&#46; Todos ellos hab&#237;an sido tratados insatisfactoriamente con corticosteroides t&#243;picos y orales y ciclosporina&#44; 10&#47;11 &#40;90&#44;9&#37;&#41; segu&#237;an tratamiento de dupilumab&#44; y 1&#47;11 &#40;9&#44;1&#37;&#41; segu&#237;an tratamiento de baricitinib&#44; sin lograr un control de la enfermedad aceptable&#46; Las caracter&#237;sticas basales se reflejan en la <a class="elsevierStyleCrossRef" href="#tbl0005">Tabla 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">En cuanto a la efectividad&#44; todos los pacientes reportaron alivio r&#225;pido del prurito&#44; que fue absoluto en el 72&#44;7&#37; de los pacientes&#59; en dichos pacientes&#44; el tiempo de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>rango intercuart&#237;lico &#40;RIC&#41; para el control fue de 4 d&#237;as &#40;2&#44;5&#8211;5&#41;&#46; Al inicio&#44; los valores de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RIC para EASI e IGA-AD fueron de 28 &#40;25&#44;50&#8211;34&#44;25&#41; y 4 &#40;3&#8211;4&#41;&#44; respectivamente&#44; el valor del &#237;ndice SCORAD fue de 58 &#40;51&#8211;60&#41;&#44; y el del &#225;rea de superficie corporal &#40;BSA&#41; afectada de 35 &#40;20&#8211;62&#44;25&#41;&#46; En cuanto a las medidas del resultado reportadas por el paciente&#44; los valores de media<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RIC para la escala num&#233;rica &#40;NRS&#41; del prurito m&#225;ximo y de DLQI fueron de 6&#44;50 &#40;5&#44;25&#8211;8&#41; y 18 &#40;13&#8211;21&#41;&#44; respectivamente&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">EASI75 &#40;&#8805;75&#37; reducci&#243;n desde el valor de EASI basal&#41; fue logrado por el 90&#44;9&#44; el 81&#44;8 y el 81&#44;8&#37; de los pacientes en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; Las puntuaciones IGA-AD de 0&#8211;1 fueron logradas por el 81&#44;8&#44; 72&#44;7 y 72&#44;7&#37; de los pacientes en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; Los valores medios de DLQI durante el seguimiento fueron de 4&#44; 2&#44; y 2 en las semanas 4&#44; 12 y 24&#44; respectivamente&#46; La eficacia del tratamiento durante el seguimiento se muestra en la <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">En cuanto a las AA&#44; los pacientes presentaron al menos una AA leve&#46; Anal&#237;ticamente&#44; todos los pacientes presentaron incrementos ligeros de los niveles de creatina quinasa en alg&#250;n momento del seguimiento&#46; Otros hallazgos fueron hipercolesterolemia &#40;54&#44;5&#37;&#41;&#44; hipertrigliceridemia &#40;18&#44;2&#37;&#41; e incremento leve de las transaminasas hep&#225;ticas &#40;9&#44;1&#37;&#41;&#46; En cuanto a trastornos infecciosos&#44; 1&#47;12 &#40;9&#44;1&#37;&#41; experimentaron un episodio de herpes z&#243;ster multimetam&#233;rico&#46; No se registraron AA cl&#237;nicos o anal&#237;ticos graves&#46; Todos los AA reportados se muestran en la <a class="elsevierStyleCrossRef" href="#tbl0010">Tabla 2</a>&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Los ensayos cl&#237;nicos MEASURE UP 1 y 2 lograron un valor EASI75 en el 76&#44;3&#37; de los pacientes en la 16&#170; semana de seguimiento&#44; mientras que nosotros observamos un valor EASI75 ligeramente mejor en las semanas 12 y 24 &#40;81&#44;8&#37; en ambas&#41;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a>&#46; En estudios previos sobre la pr&#225;ctica cl&#237;nica real con muestras de mayor tama&#241;o&#44; Pereyra-Rodriguez et al&#46; reportaron un valor de respuestas EASI75 e IGA-AD en la 16&#170; semana del 76&#44;7 y 62&#44;8&#37;&#44; respectivamente &#40;muestra de 43 pacientes&#41;&#44; lo cual es inferior a nuestros hallazgos<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a>&#46; Por otro lado&#44; Chiricozzi et al&#46; reportaron resultados m&#225;s altos en t&#233;rminos de EASI75 en la 16&#170; semana &#40;97&#44;5&#37;&#41; en una muestra de 43 pacientes<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">3</span></a>&#46; Centr&#225;ndonos en los estudios que incluyen &#250;nicamente pacientes con DA refractaria&#44; como el nuestro &#40;inefectividad de dupilumab o JAKi&#41;&#44; Feraru et al&#46; encontraron una respuesta IGA-AD similar a la de nuestro estudio en la semana 24&#170; de seguimiento en 12 adultos &#40;75&#37;&#41;&#44; mientras que De Greef et al&#46; reportaron una respuesta IGA-AD ligeramente menor &#40;71&#44;4&#37;&#41; durante el seguimiento a largo plazo<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">4&#44;5</span></a>&#46; En los estudios con seguimientos m&#225;s breves&#44; Dal Bello et al&#46; lograron un resultado EASI75 en los 10 pacientes con DA refractaria incluidos en el estudio en la 8<span class="elsevierStyleHsp" style=""></span>&#170; semana de seguimiento&#44; mientras que Napolitano et al&#46; reportaron un valor EASI75 del 75&#37; &#40;16 pacientes incluidos&#41; en la 16&#170; semana de seguimiento<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">6&#44;7</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Debemos mencionar el excelente control del prurito logrado por upadacitinib en nuestra serie &#40;72&#44;7&#37; de los pacientes frente al 60&#37; reportado en los ensayos cl&#237;nicos&#41;&#44; y el breve periodo de tiempo transcurrido hasta la remisi&#243;n del prurito de los pacientes &#40;mediana&#44; 4 d&#237;as&#41;&#44; variable no considerada en estudios previos y que debe ser de inter&#233;s&#44; dado que el prurito representa el s&#237;ntoma principal relacionado con la DA&#44; y tiene un impacto directo en la calidad de vida del paciente&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">En conclusi&#243;n&#44; nuestros hallazgos sobre eficacia son consistentes con los reportados tanto en ensayos cl&#237;nicos como en informes de la pr&#225;ctica cl&#237;nica previos&#46; Seg&#250;n nuestra experiencia&#44; upadacitinib es una opci&#243;n fiable cuando las circunstancias del paciente demandan un r&#225;pido alivio del prurito&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">La fortaleza de nuestro estudio es que se trat&#243; de una experiencia en la pr&#225;ctica cl&#237;nica real de los pacientes con DA refractaria a m&#250;ltiples tratamientos&#46; Las limitaciones principales del estudio incluyen el peque&#241;o tama&#241;o de la muestra y la recopilaci&#243;n retrospectiva de los datos&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicto de intereses</span><p id="par0055" class="elsevierStylePara elsevierViewall">Los autores declaran la ausencia de conflicto de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicto de intereses"
        ]
        1 => array:1 [
          "titulo" => "Referencias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2144
            "Ancho" => 2508
            "Tamanyo" => 244013
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">EASI75&#44; IGA-AD 0&#47;1 &#40;&#37;&#41; y SCORAD&#44; DLQI y BSA &#40;mediana&#41; a lo largo del tiempo&#46; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Investigator Global Assessment for Atopic Dermatitis validado de 0 o 1&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; DLQI&#58; Dermatology Life Quality Index&#59; BSA&#58; &#225;rea de superficie corporal&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se utiliz&#243; la prueba <span class="elsevierStyleItalic">U</span> de Mann&#8211;Whitney&#44; cuando fue necesario&#44; para calcular las diferencias estad&#237;sticas&#46;</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>0&#44;001 para las diferencias con respecto a los valores basales&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">AD&#58; dermatitis at&#243;pica&#59; NB-UVB&#58; rayos ultravioleta B de banda estrecha&#59; EASI&#58; Eczema Area and Severity Index&#59; IGA-AD&#58; Validated Investigator Global Assessment for Atopic Dermatitis&#59; SCORAD&#58; SCORing Atopic Dermatitis&#59; NRS&#58; escala num&#233;rica&#59; BSA&#58; &#225;rea de superficie corporal&#59; DLQI&#58; Dermatology Life Quality Index&#59; RIC&#58; rango intercuart&#237;lico&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#225;metro&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes&#44; n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Edad&#44; a&#241;os&#59; rango &#40;mediana&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#8211;52 &#40;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo masculino&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;45&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Duraci&#243;n de la DA&#44; a&#241;os&#59; mediana &#40;RIC&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;18&#8211;34&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedad renal&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Enfermedad hep&#225;tica&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Comorbilidades at&#243;picas&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Rinitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;45&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Asma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Conjuntivitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alergia alimentaria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;81&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dermatitis por contacto&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">F&#225;rmacos t&#243;picos previos para DA&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inhibidores de calcineurina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tratamientos sist&#233;micos previos para DA&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Baricitinib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Ciclosporina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fototerapia NB-UVB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dupilumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;90&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Basal</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EASI&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28 &#40;25&#44;50&#8211;34&#44;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IGA-AD&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#44;00&#8211;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>SCORAD&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">58 &#40;51&#8211;60&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BSA&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35 &#40;20&#8211;62&#44;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>NRS de prurito&#59; mediana &#40;RIC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;50 &#40;5&#44;25&#8211;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">DLQI&#59; mediana &#40;RIC&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;13&#8211;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3555923.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nicas y demogr&#225;ficas basales de los pacientes con dermatitis at&#243;pica grave que reciben upadacitinib</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">EA&#58; efectos adversos&#59; CK&#58; creatina quinasa&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Acn&#233;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cefalea</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Conjuntivitis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Trastorno GI</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Malestar</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hallazgos de laboratorio</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipercolesterolemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;54&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipertrigliceridemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;18&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Niveles elevados de transaminasas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Nivel elevado de CK&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Infecciosos</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Herpes z&#243;ster&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;9&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Infecciones del tracto respiratorio superior&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;27&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Reactivaci&#243;n de herpes simplex&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;36&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Graves</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Episodios cardiovasculares&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Episodios tromboemb&#243;licos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cualquier EA</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3555924.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Datos sobre seguridad de los pacientes con dermatitis at&#243;pica grave que reciben upadacitinib</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Referencias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:7 [
            0 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis &#40;Measure Up 1 and Measure Up 2&#41;&#58; results from two replicate double-blind&#44; randomised controlled phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Guttman-Yassky"
                            1 => "H&#46;D&#46; Teixeira"
                            2 => "E&#46;L&#46; Simpson"
                            3 => "K&#46;A&#46; Papp"
                            4 => "A&#46;L&#46; Pangan"
                            5 => "A&#46; Blauvelt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00588-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "2151"
                        "paginaFinal" => "2168"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34023008"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of severe atopic dermatitis with upadacitinib in clinical practice&#58; short-term efficacy and safety results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;J&#46; Pereyra-Rodriguez"
                            1 => "P&#46; Herranz"
                            2 => "I&#46; Figueras-Nart"
                            3 => "B&#46; Perez"
                            4 => "M&#46; Elosua"
                            5 => "C&#46; Munera-Campos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.18176/jiaci.0831"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Investig Allergol Clin Immunol"
                        "fecha" => "2023"
                        "volumen" => "33"
                        "paginaInicial" => "211"
                        "paginaFinal" => "213"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35671128"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis&#58; a multicentric&#44; prospective&#44; real-world&#44; cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Chiricozzi"
                            1 => "N&#46; Gori"
                            2 => "A&#46; Narcisi"
                            3 => "A&#46; Balato"
                            4 => "A&#46; Gambardella"
                            5 => "M&#46; Ortoncelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Drugs R D"
                        "fecha" => "2022"
                        "volumen" => "22"
                        "paginaInicial" => "245"
                        "paginaFinal" => "252"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis &#8211; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Feraru"
                            1 => "M&#46;J&#46; Nevet"
                            2 => "L&#46; Samuelov"
                            3 => "E&#46; Hodak"
                            4 => "E&#46; Avitan-Hersh"
                            5 => "M&#46; Ziv"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18311"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "e832"
                        "paginaFinal" => "e833"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35680538"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; De Greef"
                            1 => "P&#46;D&#46; Ghislain"
                            2 => "L&#46; de Montjoye"
                            3 => "M&#46; Baeck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12325-023-02490-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Ther"
                        "fecha" => "2023"
                        "volumen" => "40"
                        "paginaInicial" => "2509"
                        "paginaFinal" => "2514"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36944819"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Upadacitinib in patients with resistant atopic dermatitis&#58; a retrospective case-series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46; Dal Bello"
                            1 => "D&#46; Schena"
                            2 => "G&#46; Girolomoni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.18139"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2022"
                        "volumen" => "36"
                        "paginaInicial" => "1499"
                        "paginaFinal" => "1500"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35398938"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis&#58; a 16-week real-life dual-centre experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Napolitano"
                            1 => "L&#46; Potestio"
                            2 => "K&#46; Hansel"
                            3 => "R&#46; Marietti"
                            4 => "I&#46; Piscitelli"
                            5 => "G&#46; Fabbrocini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ced/llac078"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol"
                        "fecha" => "2023"
                        "volumen" => "48"
                        "paginaInicial" => "247"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36763761"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024002825/v1_202406021150/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6160"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas cient&#237;fico-cl&#237;nicas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000006/v1_202406021150/S0001731024002825/v1_202406021150/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024002825?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 35 14 49
2024 Octubre 204 73 277
2024 Septiembre 205 39 244
2024 Agosto 246 94 340
2024 Julio 204 43 247
2024 Junio 226 67 293
2024 Mayo 132 52 184
2024 Abril 204 73 277

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?